|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 11400 Rockville Pike |
Address2 |
|
| City | Rockville |
State | MD |
Zip Code | 20852 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401104864-12
|
||||||||
|
6. House ID# 440290001
|
||||||||
| TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kelly Corredor |
Date | 10/17/2025 11:28:41 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment.
Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies.
Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits.
Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products.
Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas.
Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing.
Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces.
Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder.
Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment.
Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies.
Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits.
Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products.
Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas.
Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing.
Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces.
Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder.
Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment.
Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies.
Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits.
Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products.
Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas.
Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing.
Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces.
Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder.
Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment.
Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies.
Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits.
Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products.
Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas.
Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing.
Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces.
Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder.
Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment.
Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies.
Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits.
Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products.
Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas.
Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing.
Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces.
Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder.
Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment.
Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M).
Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts.
Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies.
Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits.
Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products.
Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas.
Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing.
Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces.
Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder.
Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |